Akari Therapeutics Secures $5.5M Private Placement at Deep Discount, Facing Extreme Dilution

summarizeSummary

Akari Therapeutics announced a $5.5 million private placement of ADSs and warrants at a deep discount to market price, providing crucial capital but causing extreme dilution.

check_boxKey Events

• Secures $5.5 Million Capital

  The company entered into a securities purchase agreement for a private placement expected to generate approximately $5.5 million in gross proceeds. This finalizes the terms and pricing of the offering initiated with the S-1 filing on 2026-05-08.

• Deep Discount Pricing

  Units (ADSs or prefunded warrants plus three series of warrants) are priced at $3.74, a substantial discount to the current stock price of $15.16.

• Extreme Dilution Potential

  The offering involves 1,470,588 ADSs (or prefunded warrants) and three series of warrants (Series H, I, J), each exercisable for one ADS, representing significant potential future dilution. An additional 117,647 ADSs will be issued to the placement agent.

• Addresses Going Concern Warning

  This capital raise is critical for the company, which recently reported a "going concern" warning in its 2026-05-19 10-Q filing and a cash runway extending only into June 2026.

auto_awesomeAnalysis

Akari Therapeutics has finalized a critical $5.5 million private placement offering, which is essential for the company's immediate survival given its recent "going concern" warning and limited cash runway. However, the terms are highly dilutive for existing shareholders. The offering is priced at a significant discount to the current market price, and includes multiple series of warrants that could lead to substantial additional dilution upon exercise.